1-20 of 123
Charles M. Perou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO1-15-10: Lower pre-treatment B-cell gene expression signatures correspond with improved overall survival with palbociclib + endocrine therapy in HR+/HER2- metastatic breast cancer: a biomarker analysis from the GEICAM/2013-02 PEARL trial

Yash Agrawal, Aranzazu Fernandez-Martinez, Miguel Gil-Gil, Christoph Zielinski, Manuel Ruíz- Borrego, Eva Ciruelos, Montserrat Muñoz, Mireia Margelí, Begoña Bermejo, Antonio Antón, Zsuzsanna Kahan, Tibor Csöszi, José L Alonso-Romero, Jose Angel García-Sáenz, Pedro Sánchez-Rovira, Elena Álvarez, J. Ignacio Chacón, Santiago González-Santiago, César A Rodríguez, Sonia Servitja, Adam D. Pfefferle, Jesús Herranz, Yuan Liu, Lisa A. Carey, Isabel Romero - Camarero, Rosalía Caballero, Charles M. Perou, Miguel Martín
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO1-15-10.
https://doi.org/10.1158/1538-7445.SABCS23-PO1-15-10
Published: 02 May 2024
View article titled, Abstract PO1-15-10: Lower pre-treatment B-cell gene expression signatures correspond with improved overall survival with palbociclib + endocrine therapy in HR+/HER2- metastatic breast cancer: a biomarker analysis from the GEICAM/2013-02 PEARL trial
Journal Articles

Abstract PO2-01-06: Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in HER2+ early-breast cancer (EBC)

Aranzazu Fernandez-Martinez, Maki Tanioka, Sung Gwe Ahn, Paola Zagami, Tomás Pascual, Mattia Rediti, Gong Tang, Katherine A Hoadley, David Venet, Naim U. Rashid, Patty Spears, Judith Bliss, Jens Huober, Priya Rastogi, Md N. Islam, Javier Cortés, Antonio Llombart-Cussac, Sandra Swain, Christos Sotiriou, Aleix Prat, Charles M Perou, Lisa Carey
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-01-06.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-01-06
Published: 02 May 2024
View article titled, Abstract PO2-01-06: Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in HER2+ early-breast cancer (EBC)
Journal Articles

Abstract PO3-16-03: Investigating HER2DX genomic assay concordance within HER2-positive breast cancer

Fara Brasó-Maristany, Laia Paré, Guillermo Villacampa, Mercedes Marín-Aguilera, Paul Spellman, Adrienne Waks, Ian Krop, Esther Sanfeliu, Zhequi Li, Patricia Galván, Eva Hernández-Illán, Pedro Jares, Joan Antón Puig-Butillé, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, Sara Tolaney, Otto Metzger, Kornelia Polyak, Aleix Prat
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-16-03.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-16-03
Published: 02 May 2024
View article titled, Abstract PO3-16-03: Investigating HER2DX genomic assay concordance within HER2-positive breast cancer
Journal Articles

Abstract PO3-05-06: Targeting PAM50 HER2-Enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer: results of the SOLTI-1502 ARIANNA trial

Mafalda Oliveira, Tomás Pascual, Sonia Pernas, Mireia Margelí, Salvador Blanch, Barbara Adamo, Francisco Javier Salvador Bofill, Xavier Gonzalez-Farré, Samyukta Chillara, Patricia Galván, Esther Sanfeliu, Paula Blasco, Valeria Sirenko, Alejandra Espinosa, Charles M Perou, Aleix Prat, Luis Manso
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-05-06.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-05-06
Published: 02 May 2024
View article titled, Abstract PO3-05-06: Targeting PAM50 HER2-Enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer: results of the SOLTI-1502 ARIANNA trial
Journal Articles

Abstract PO2-15-08: Exploring Essential Immune Genes Linked to Pathological Complete Response and Survival in Early-Stage Triple-Negative Breast Cancer (TNBC) after Chemotherapy Treatment

Fara Brasó-Maristany, Laia Paré, Benedetta Conte, Laura Angelats, Ana Vivancos, Joel S Parker, Charles M. Perou, Patricia Villagrasa, Aleix Prat
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-15-08.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-15-08
Published: 02 May 2024
View article titled, Abstract PO2-15-08: Exploring Essential Immune Genes Linked to Pathological Complete Response and Survival in Early-Stage Triple-Negative Breast Cancer (TNBC) after Chemotherapy Treatment
Journal Articles

Abstract PO2-15-07: HER2DX genomic assay in triple-negative breast cancer (TNBC) patients treated with 12-weeks of neoadjuvant chemotherapy: a correlative analysis from WSG-ADAPT-TN phase II trial

Oleg Gluz, Fara Brasó-Maristany, Ulrike Nitz, Laia Paré, Matthias Christgen, Guillermo Villacampa, Benedetta Conte, Sherko Kuemmel, Ronald Kates, Cornelia Kolberg-Liedtke, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Ana Vivancos, Rachel Wuerstlein, Joel S. Parker, Monika Graeser, Charles M. Perou, Christine zu Eulenburg, Patricia Villagrasa, Hans-Heinrich Kreipe, Aleix Prat, Nadia Harbeck
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-15-07.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-15-07
Published: 02 May 2024
View article titled, Abstract PO2-15-07: HER2DX genomic assay in triple-negative breast cancer (TNBC) patients treated with 12-weeks of neoadjuvant chemotherapy: a correlative analysis from WSG-ADAPT-TN phase II trial
Journal Articles

Abstract PO2-15-06: ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2-) advanced breast cancer following endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial

Fara Brasó-Maristany, Javier Cortés, José Manuel Pérez-García, Rosario Vega-León, Laia Paré, Guillermo Villacampa, Judit Matito, Francisco Pardo, Marina Gomez-Rey, Mario Mancino, Elena Martínez-García, Carmen Mora Gallardo, Leonardo Mina, Florence Dalenc, Meritxell Bellet- Ezquerra, Manuel Ruíz - Borrego, Miguel Gil-Gil, Peter Schmid, Charles M. Perou, Joel S. Parker, Patricia Villagrasa, Ana Vivancos, Aleix Prat, Antonio Llombart-Cussac
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-15-06.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-15-06
Published: 02 May 2024
View article titled, Abstract PO2-15-06: ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2-) advanced breast cancer following endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial
Journal Articles

Abstract PO4-19-05: OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy (Alliance A012103)

Sara Tolaney, Karla Ballman, Charles M Perou, David Cescon, Margaret Gatti-Mays, Victoria Blinder, Shoshana Rosenberg, Elizabeth Mittendorf, Anna Weiss, Hope Rugo, Alice Ho, Dana Casey, Baljit Singh, Fabrice Smieliauskas, Yara Abdou, Vijay Damarla, Jane Meisel, Lisa Carey, Ann Partridge
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-19-05.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-19-05
Published: 02 May 2024
View article titled, Abstract PO4-19-05: OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy (Alliance A012103)
Journal Articles

Abstract PO4-06-04: Understanding metastasis mixed-treatment responses through genomic analyses

Susana Garcia-Recio, Paola Zagami, Amy Wheless, Kerry Thomas, Lisa Carey, Charles M Perou
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-06-04.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-06-04
Published: 02 May 2024
View article titled, Abstract PO4-06-04: Understanding metastasis mixed-treatment responses through genomic analyses
Journal Articles

Abstract 5213: Evaluation of HER2DX risk-score in residual disease (RD) from HER2-positive (HER2+) early breast cancer (EBC) patients (pts) following neoadjuvant trastuzumab and pertuzumab (HP)-based therapy: An exploratory analysis from the PHERGain trial

José Manuel Pérez-García, Fara Brasó-Maristany, Elena Martínez-García, Carmen Mora Gallardo, Eileen Shimizu, Olga Boix Sánchez, Jose Rodríguez-Morató, Mario Mancino, Laia Paré, Guillermo Villacampa, Mercedes Marín-Aguilera, Patricia Galván, Ana Vivancos, Patricia Villagrasa, Joel Parker, Charles M. Perou, Antonio Llombart-Cussac, Javier Cortés, Aleix Prat
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5213.
https://doi.org/10.1158/1538-7445.AM2024-5213
Published: 22 March 2024
View article titled, Abstract 5213: Evaluation of HER2DX risk-score in residual disease (RD) from HER2-positive (HER2+) early breast cancer (EBC) patients (pts) following neoadjuvant trastuzumab and pertuzumab (HP)-based therapy: An exploratory analysis from the PHERGain trial
Journal Articles

Abstract 1750: Decoding breast cancer: Unraveling subtype and model differences through multi-model single-cell RNA sequencing data integration

Julia E. Altman, Carson J. Walker, Emily K. Zboril, Nicole S. Hairr, Rachel K. Myrick, David C. Boyd, Jennifer E. Koblenski, Madhavi Puchalapalli, Bin Hu, Mikhail G. Dozmorov, Xi Chen, Yunshun Chen, Charles M. Perou, Brian D. Lehmann, Jane E. Visvader, Amy L. Olex, J. Chuck Harrell
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1750.
https://doi.org/10.1158/1538-7445.AM2024-1750
Published: 22 March 2024
View article titled, Abstract 1750: Decoding breast cancer: Unraveling subtype and model differences through multi-model single-cell RNA sequencing data integration
Journal Articles

Abstract 2542: Real-world validation of the PurIST classifier demonstrates enhanced therapy selection for pancreatic ductal adenocarcinoma (PDAC) patients

Stephane Wenric, James M. Davison, John Guittar, Gregory M. Mayhew, Kirk Beebe, Alia Zander, Seung Won Hyun, Kyle Beauchamp, Michael V. Milburn, Vincent Chung, Tanios S. Bekaii-Saab, Charles M. Perou
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2542.
https://doi.org/10.1158/1538-7445.AM2024-2542
Published: 22 March 2024
View article titled, Abstract 2542: Real-world validation of the PurIST classifier demonstrates enhanced therapy selection for pancreatic ductal adenocarcinoma (PDAC) patients
Journal Articles

Abstract IA05: Leveraging preclinical models of triple negative breast cancer for translational research

Jeffrey M Rosen, Diego Pedroza, Na Zhao, Xiang H-F Zhang, Charles M Perou
Journal: Cancer Research
Cancer Res (2024) 84 (3_Supplement_1): IA05.
https://doi.org/10.1158/1538-7445.ADVBC23-IA05
Published: 01 February 2024
View article titled, Abstract IA05: Leveraging preclinical models of triple negative breast cancer for translational research
Journal Articles

Abstract B034: Characterization of MHC-I-mediated immune evasion in triple-negative breast cancer using human transcriptomic datasets and immunocompetent mouse models

Constandina E O'Connell, Brooke M Felsheim, Aranzazu Fernandez-Martinez, Kevin R Mott, Charles M Perou
Journal: Cancer Research
Cancer Res (2024) 84 (3_Supplement_1): B034.
https://doi.org/10.1158/1538-7445.ADVBC23-B034
Published: 01 February 2024
View article titled, Abstract B034: Characterization of MHC-I-mediated immune evasion in triple-negative breast cancer using human transcriptomic datasets and immunocompetent mouse models
Journal Articles

Abstract A012: Mre11 mediates cGAS activation and tumor suppression through ZBP1-dependent necroptosis in breast cancer

Minguk Jo, Rashmi J. Kumar, Chien-Chu Lin, Joshua A. Boyer, Jamshaid A. Shahir, Katerina Fagan-Solis, Dennis A. Simpson, Cheng Fan, Christine E. Foster, Anna M. Goddard, Lynn M. Lerner, Simon W. Ellington, Qinhong Wang, Ying Wang, Alice Y. Ho, Pengda Liu, Charles M. Perou, Qi Zhang, Robert K. McGinty, Jeremy E. Purvis, Gaorav P. Gupta
Journal: Cancer Research
Cancer Res (2024) 84 (1_Supplement): A012.
https://doi.org/10.1158/1538-7445.DNAREPAIR24-A012
Published: 09 January 2024
View article titled, Abstract A012: Mre11 mediates cGAS activation and tumor suppression through ZBP1-dependent necroptosis in breast cancer
Journal Articles

Abstract 5754: Determining the regulatory logic of breast cancer cells using single-cell multi-omics

Matthew J. Regner, Aatish Thennavan, Susana Garcia-Recio, Kamila Wisniewska, Philip M. Spanheimer, Joel S. Parker, Charles M. Perou, Hector L. Franco
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5754.
https://doi.org/10.1158/1538-7445.AM2023-5754
Published: 04 April 2023
View article titled, Abstract 5754: Determining the regulatory logic of breast cancer cells using single-cell multi-omics
Journal Articles

Abstract P1-13-16: Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)

Natàlia Lorman-Carbó, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, Patricia Galván, Nuria Chic, Barbara Adamo, Maria Vidal, Montserrat Muñoz, Charles M. Perou, Joaquín Gavilá, Tomás Pascual, Aleix Prat, Fara Brasó-Maristany
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P1-13-16.
https://doi.org/10.1158/1538-7445.SABCS22-P1-13-16
Published: 01 March 2023
View article titled, Abstract P1-13-16: Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
Journal Articles

Abstract PD1-08: PAM50 and 21-gene recurrence scores in younger and Black women with breast cancer

Sanah Vohra, Sarah Van Alsten, Joannie M. Ivory, Alina Hamilton, Xiaohua Gao, Erin Kirk, Joseph Nsonwu-Farley, Ebonee Butler, Brianna Taffe, Charles M. Perou, Lisa Carey, Melissa Troester
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD1-08.
https://doi.org/10.1158/1538-7445.SABCS22-PD1-08
Published: 01 March 2023
View article titled, Abstract PD1-08: PAM50 and 21-gene recurrence scores in younger and Black women with breast cancer
Journal Articles

Abstract P5-14-02: Identifying oncogenic enhancer elements in TNBC of the Basal-like subtype using single-cell ATAC-seq and RNA-seq

Matthew J. Regner, Aatish Thennavan, Kamila Wisniewska, Susana Garcia-Recio, Raul Mendez-Giraldez, Philip Spanheimer, Charles M. Perou, Hector L. Franco
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-14-02.
https://doi.org/10.1158/1538-7445.SABCS22-P5-14-02
Published: 01 March 2023
View article titled, Abstract P5-14-02: Identifying oncogenic enhancer elements in TNBC of the Basal-like subtype using single-cell ATAC-seq and RNA-seq
Journal Articles

Abstract PD18-04: Prognostic implications of PIK3CA mutation by hormone receptor status and intrinsic subtype in early stage HER2-positive breast cancer: a correlative analysis from CALGB 40601

Paola Zagami, Aranzazu Fernandez-Martinez, Naim U. Rashid, Katherine A Hoadley, Patty Spears, Charles M. Perou, Lisa Carey
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD18-04.
https://doi.org/10.1158/1538-7445.SABCS22-PD18-04
Published: 01 March 2023
View article titled, Abstract PD18-04: Prognostic implications of PIK3CA mutation by hormone receptor status and intrinsic subtype in early stage HER2-positive breast cancer: a correlative analysis from CALGB 40601